相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
Hiroaki Ikesue et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)
Comprehensive Study of the Risk Factors for Medication-Related Osteonecrosis of the Jaw Based on the Japanese Adverse Drug Event Report Database
Shinya Toriumi et al.
PHARMACEUTICALS (2020)
Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis
Alvaro Limones et al.
MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL (2020)
Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline
Noam Yarom et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report database
Ayaka Inada et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2019)
Denosumab-related osteonecrosis of the jaw: A retrospective study
Claire Egloff-Juras et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2018)
Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab
Tine Loyson et al.
ACTA CLINICA BELGICA (2018)
Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases
Sven Otto et al.
CANCER TREATMENT REVIEWS (2018)
Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw
Tomoko Higuchi et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY (2018)
Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw
Toshiyuki Yoneda et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2017)
Survival after bone metastasis by primary cancer type: a Danish population-based cohort study
Elisabeth Svensson et al.
BMJ OPEN (2017)
Drug-induced gingival hyperplasia: a retrospective study using spontaneous reporting system databases
Haruna Hatahira et al.
JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES (2017)
Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS)
Xiaoyan Zhang et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
Alison T. Stopeck et al.
SUPPORTIVE CARE IN CANCER (2016)
Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events
Mitsuhiro Nakamura et al.
JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES (2015)
A tutorial on sensitivity analyses in clinical trials: the what, why, when and how
Lehana Thabane et al.
BMC MEDICAL RESEARCH METHODOLOGY (2013)
Illustration of the Weibull Shape Parameter Signal Detection Tool Using Electronic Healthcare Record Data
Odile Sauzet et al.
DRUG SAFETY (2013)
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
F. Saad et al.
ANNALS OF ONCOLOGY (2012)
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab
David L. Lacey et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Denosumab and bisphosphonates: Different mechanisms of action and effects
Roland Baron et al.
BONE (2011)
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
David H. Henry et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim Fizazi et al.
LANCET (2011)
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Alison T. Stopeck et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Clinical features of metastatic bone disease and risk of skeletal morbidity
Robert E. Coleman
CLINICAL CANCER RESEARCH (2006)
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic
RE Marx
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2003)
A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions
EP van Puijenbroek et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2002)
分享论文
